(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients with chronic rhinosinusitis with nasal polyps (CRSwNP), reducing both nasal polyp size and congestion compared to a placebo. The WAYPOINT trial … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, Amgen, AstraZeneca, chronic rhinosinusitis, Dr. Brian Lipworth, Dr. Joseph Han, Healthcare, Nasal Polyp Symptoms, partnership, safety, Sharon Barr, sustainability, tezepelumab, Tezspire, USA
(IN BRIEF) Logicor has extended its lease with DHL Poland at its Mysłowice logistics park, where DHL occupies 12,200 sqm of warehouse space and provides logistical support for Bausch Health Poland. The facility, tailored for pharmaceutical needs with advanced temperature … Read the full press release
Posted in Business, Environment, Financial, Government, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Poland, Real Estate, Technology, Transportation & Logistics, United Kingdom
Tagged DHL Poland, Logicor, Mysłowice, partnership, Pharmaceutical Logistics Hub, Piotr Brycki, sustainability
(IN BRIEF) The European Medicines Agency has approved Dupixent as the first treatment for eosinophilic esophagitis (EoE) in young children aged one to 11, marking a significant step in managing this condition in a critical developmental phase. The approval is … Read the full press release
Posted in Business, Education, European Union, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Dr. George Yancopoulos, Dr. Houman Ashrafian, Dupixent, eosinophilic esophagitis, EU, European Medicines Agency (EMA), Healthcare, Regeneron, safety, Sanofi, treatment, wellness, Young Children
(IN BRIEF) SGS has introduced advanced laser diffraction technology at its Wavre, Belgium lab, enhancing its ability to measure droplet sizes in spray drug delivery systems. This investment in Malvern Spraytec technology allows for real-time data collection during the spray … Read the full press release
Posted in Belgium, Business, Environment, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Belgium, investment, Laser Diffraction Technology, Malvern Spraytec laser diffraction system, partnership, Pharmaceutical Spray Testing, safety, SGS, sustainability
(IN BRIEF) Evotec SE has sold its chemical API-focused manufacturing site, Evotec DS GmbH, to Monacum Partners as part of its “Priority Reset” strategy to focus on core growth areas. The Halle/Westphalia-based facility, now renamed DAPIN GmbH, will continue its … Read the full press release
Posted in Business, Chemicals, Environment, Financial, Germany, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged acquisition, API Manufacturing Site, DAPIN GmbH, Evotec, Monacum Partners, partnership, sustainability
(IN BRIEF) QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel has received FDA clearance, enabling faster and more accurate diagnosis of critical CNS infections like meningitis and encephalitis. This panel, the fourth QIAstat-Dx test approved in the U.S. in 2024, uses real-time PCR to … Read the full press release
(IN BRIEF) Accenture has invested in 1910 Genetics, a biotech firm leveraging AI-driven lab automation to enhance drug discovery for small and large molecule therapies. This partnership aims to provide biopharma clients with a powerful AI platform, streamlining the drug … Read the full press release
Posted in Artificial Intelligence (AI), Business, Environment, Financial, Government, Healthcare, Industrial, Ireland, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged 1910 Genetics, Accenture, AI-Driven Solutions, Dr. Cecil Lynch, Dr. Jen Nwankwo, Dr. Kailash Swarna, drug discovery, partnership, Petra Jantzer, sustainability, Tom Lounibos, USA
(IN BRIEF) Roche announced the publication of pivotal phase III results for its Itovebi™ (inavolisib)-based regimen at the Clinical Trials in Alzheimer’s Disease congress, demonstrating a 57% reduction in the risk of disease progression or death in patients with HR-positive, … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Dr. Komal Jhaveri, Healthcare, HR-Positive Breast Cancer, Itovebi, Levi Garraway, PIK3CA mutation, Roche, safety, Survival Benefits, wellness
(IN BRIEF) At the CTAD 2024 congress in Madrid, Roche presented new data on its Elecsys® Amyloid Plasma Panel and Elecsys ptau181, demonstrating their effectiveness in diagnosing Alzheimer’s disease. The blood-based test showed a negative predictive value of 96.2% in … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Media, News, Pharma & Biotech, Science, Spain, Switzerland, Technology
Tagged Alzheimer, Clinical Trials in Alzheimer’s Disease congress (CTAD) 2024, diagnostics, Elecsys ptau181, Elecsys® Amyloid Plasma Panel, Healthcare, Matt Sause, Roche, Spain
(IN BRIEF) QIAGEN has announced FDA clearance for its QIAstat-Dx Respiratory Panel Mini, marking the third such approval for the QIAstat-Dx system in 2024. Tailored for outpatient settings, this panel quickly detects five common respiratory pathogens—including influenza strains and SARS-CoV-2—enabling … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged FDA approval, influenza strains, Nadia Aelbrecht, Outpatient Respiratory Diagnostics, QIAGEN, QIAstat-Dx Mini Panel, Rapid Results, safety, SARS-CoV-2
(IN BRIEF) AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union as an add-on treatment for adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare and severe form of vasculitis. The approval follows positive results from the MANDARA Phase … Read the full press release
Posted in Business, European Union, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AstraZeneca, Bernhard Hellmich, Eosinophilic Granulomatosis with Polyangiitis (EGPA), EU, Fasenra, patients, Rare Vasculitis, Ruud Dobber, safety
(IN BRIEF) AstraZeneca and Ionis’ drug Wainzua (eplontersen) has been recommended for approval in the European Union for treating hereditary transthyretin-mediated amyloidosis (ATTRv-PN) in adults with stage 1 or 2 polyneuropathy. Based on the positive results from the NEURO-TTRansform Phase … Read the full press release
Posted in Business, European Union, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, Dr. Laura Obici, EU, Hereditary Amyloidosis (ATTRv-PN), Ionis Pharmaceuticals, safety, Wainzua
(IN BRIEF) GSK and the University of Cambridge have announced a £50 million, five-year collaboration called the Cambridge-GSK Translational Immunology Collaboration (CG-TIC) to accelerate research and development in kidney and respiratory diseases. The initiative combines GSK’s expertise in immunology and … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AI, Cambridge University, Cambridge-GSK Translational Immunology Collaboration (CG-TIC), GSK, immunology, investment, Kidney and Respiratory Diseases, Nicolas Wisniacki, partnership, Peter Kyle, Professor David Thomas, safety, sustainability, Tony Wood
(IN BRIEF) Novo Nordisk’s SOUL trial has shown that oral semaglutide reduces the risk of major adverse cardiovascular events (MACE) by 14% in adults with type 2 diabetes and established cardiovascular disease or chronic kidney disease. The trial involved 9,650 … Read the full press release
(IN BRIEF) Sanofi and CD&R have entered exclusive negotiations for CD&R to acquire a 50% controlling stake in Opella, Sanofi’s consumer healthcare business, while Sanofi retains a significant share. The partnership aims to support Opella’s growth as a global leader … Read the full press release
Posted in Business, Environment, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged acquisition, Allegra, CDR, Doliprane, expansion, France, Healthcare, Julie Van Ongevalle, Opella, partnership, Paul Hudson, Sanofi
(IN BRIEF) Novo Nordisk’s Alhemo® (concizumab) has been recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). If approved, Alhemo® will become the first once-daily subcutaneous prophylactic treatment for people aged 12 … Read the full press release
Posted in Business, Denmark, Environment, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Alhemo®, Haemophilia A and B with Inhibitors, Novo Nordisk, Once-Daily Subcutaneous Treatment, safety, Stephanie Seremetis, sustainbility
(IN BRIEF) Sanofi and Orano Med have partnered to accelerate the development of next-generation radioligand therapies (RLTs) for rare cancers. By combining their expertise, they aim to advance treatments using lead-212 (212Pb) alpha-emitting isotopes, which target and destroy cancer cells … Read the full press release
Posted in Business, Environment, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Cancer Therapies, Nicolas Maes, Orano Med, partnership, Paul Hudson, radioligand therapies (RLTs), rare cancers, safety, Sanofi, sustainability, USA
HET NIEUWE INTELLISENSE AFIB-ALGORITME ONTDEKT MOGELIJKE ATRIUMFIBRILLATIE BIJ ELKE CONTROLE VAN DE BLOEDDRUK, VERBETERT VROEGE DETECTIE EN MOGELIJKE PREVENTIE VAN ERNSTIGE COMPLICATIES (IN HET KORT) OMRON Healthcare introduceert nieuwe bloeddrukmeters met een door AI aangedreven technologie voor het detecteren van … Read the full press release
Posted in Artificial Intelligence (AI), Electronics & Machinery, Healthcare, Netherlands, News, Pharma & Biotech, Technology
Tagged AFib, AFib-detectie, AI-aangedreven AFib-detectietechnologie, atriumfibrillatie, Ayumu Okada, bloeddruk, bloeddrukmeters, cardiogene cerebrale embolie, door AI aangestuurd algoritme, ESC2024, gezondheidstechnologie, hersenbloeding, HRS2024, Intellisense AFib, Intellisense AFib-algoritme, Lucia Prada, M6 Comfort AFib-, M7 Intelli IT AFib-, OMRON Healthcare, onregelmatige hartritmes, X7 smart AFib-, zelf monitoren van de gezondheid, zelflerende systemen
LE NOUVEL ALGORITHME INTELLISENSE AFIB DÉTECTE UNE ÉVENTUELLE FIBRILLATION AURICULAIRE LORS DE CHAQUE CONTRÔLE DE LA PRESSION ARTÉRIELLE, AMÉLIORANT AINSI LA DÉTECTION PRÉCOCE ET LA PRÉVENTION ÉVENTUELLE DE COMPLICATIONS GRAVES (ACTUALITÉ EN BREF) OMRON Healthcare a dévoilé une nouvelle gamme … Read the full press release
Posted in Artificial Intelligence (AI), Electronics & Machinery, France, Healthcare, Pharma & Biotech, Technology
Tagged accident vasculaire cérébral, algorithme alimenté par l’IA, algorithme Intellisense AFib, Ayumu Okada, détection de la fibrillation auriculaire alimentée par l’IA, ESC 2024, FA, fibrillation auriculaire, HRS 2024, Intellisense AFib, Lucia Prada, l’apprentissage automatique, l’autosurveillance de santé, M6 Comfort AFib, M7 Intelli IT AFib, mesure de la pression artérielle, OMRON Healthcare, patients hypertendus, pression artérielle, rythmes cardiaques irréguliers, surveillance médicale à domicile, technologies de la santé, tensiomètres, X7 smart AFib
IL NUOVO ALGORITMO INTELLISENSE AFIB RILEVA UNA POSSIBILE FIBRILLAZIONE ATRIALE AD OGNI CONTROLLO DELLA PRESSIONE SANGUIGNA, INCREMENTANDO LE POSSIBILITÀ DI RILEVAZIONE PRECOCE E PREVENZIONE DI COMPLICAZIONI POTENZIALMENTE GRAVI (NOTIZIA IN BREVE) OMRON Healthcare ha lanciato una nuova gamma di misuratori … Read the full press release
Posted in Artificial Intelligence (AI), Electronics & Machinery, Healthcare, Italy, Pharma & Biotech, Technology
Tagged AFib, algoritmo basato sull’IA, algoritmo Intellisense AFib, apparecchiature mediche, Ayumu Okada, cardiaco irregolare, cardiopatie, cardiovascolare, controllo della pressione sanguigna, embolia cerebrale cardiogena, ESC2024, fibrillazione atriale, gestione della salute, HRS2024, ictus, Intellisense AFib, l'apprendimento automatico, Lucia Prada, M6 Comfort AFib, M7 Intelli IT AFib, malattie cardiache, misuratori della pressione, monitoraggio della salute a domicilio, OMRON Healthcare, pazienti ipertesi, pressione sanguigna, Rilevamento AFib, rilevamento della fibrillazione atriale, rilevamento della fibrillazione atriale (AFib) basata sull’IA, rilevare una possibile fibrillazione atriale, ritmi cardiaci irregolari, tecnologia a scopo sanitario, tecnologia Intellisense AFib, X7 smart AFib, zero cardiovascolari, zero malattie cerebrovascolari
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?